摘要
目的:观察马来酸依那普利联合阿替洛尔治疗慢性心力衰竭的疗效和安全性。方法:将128例慢性心力衰竭患者随机均分为观察组和对照组。对照组患者卧床休息,给予抗心力衰竭药、强心药、利尿药、硝酸酯类药等常规治疗。观察组患者在对照组治疗的基础上给予马来酸依那普利片初始剂量2.5 mg、口服、qd,第2周剂量增加至5.0 mg、口服、qd+阿替洛尔片12.5 mg、口服、qd,第2周剂量增加至25 mg、口服、qd。两组患者均治疗3周后评价临床疗效,治疗前后左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)、收缩压(SBP)、舒张压(DBP)及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,两组比较差异有统计学意义(P<0.01)。治疗前两组患者LVEDD、LVESD、LVEF、SBP、DBP差异无统计学意义。治疗后两组患者LVEDD、LVESD、SBP、DBP均显著低于同组治疗前,且观察组LVEDD、LVESD低于对照组;LVEF显著高于同组治疗前,且观察组高于对照组,差异均有统计学意义(P<0.01);但两组间SBP、DBP比较,差异无统计学意义(P>0.05)。两组患者治疗期间均未见明显不良反应发生。结论:马来酸依那普利联合阿替洛尔治疗慢性心力衰竭较常规治疗疗效更显著,安全性较好。
OBJECTIVE： To observe therapeutic efficacy and safety of enalapril maleate combined with atenolol in the treatment of chronic heart failure （CHF）. METHODS： 128 patients with CHF were randomly divided into observation group and control group. Control group rested in bed and received routine therapy as agents for heart failure, cardiotonic drug, diuretic and nitric acid ester. Observation group was additionally treated with Enalapril maleate tablet （with initial dose of 2.5 mg orally once a day, increasing to 5.0 mg at second week once a day orally） combined with atenolol （12.5 mg orally once a day, increasing to 25 mg at second week once a day orally）. Therapeutic efficacies of 2 groups were observed after 3 weeks of treatment. Clinical efficacies of 2 groups were observed, and LVEDD, LVESD, LVEF, SBP, DBP and the occurrence of ADR were observed before and after treatment. RESULTS： The total effective rate of the observation group was significantly higher than that of control group（P〈0.01 ）. LVEDD, LVESD, LVEF, SBP and DBP of 2 groups had no statistically significant difference before treatment. LVEDD, LVESD, SBP and DBP of 2 groups after treatment were significantly lower than before; LVEDD and LVESD of observation group were low- er than those of control group; LVEF after treatment was significantly higher than before, and that of observation group was higher than before; there was statistical significance （P〈0.01）. There was no statistical significance of SBP and DBP between 2 groups. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： Enalapril maleate combined with atenolol is more effective than routine treatment in the treatment of CHF and has good safety.
出处
《中国药房》
CAS
北大核心
2015年第3期314-316,共3页
China Pharmacy
